RESEARCH ARTICLE


Vaccines for Papillomavirus (HPV) Infection



C. Rodríguez-Cerdeira*, 1, A. Alba2
1 Dermatology Department, CHUVI & University of Vigo, Vigo, Spain
2 Centre for Molecular and Cellular Studies, Lugo, Spain


Article Metrics

CrossRef Citations:
0
Total Statistics:

Full-Text HTML Views: 18
Abstract HTML Views: 329
PDF Downloads: 192
Total Views/Downloads: 539
Unique Statistics:

Full-Text HTML Views: 17
Abstract HTML Views: 199
PDF Downloads: 119
Total Views/Downloads: 335



© 2009 Rodríguez-Cerdeira and Alba

open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: https://creativecommons.org/licenses/by/4.0/legalcode. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

* Address correspondence to this author at the Department of Dermatology, CHUVI, Meixoeiro Hospital & University of Vigo, 36200 Vigo (Galicia), Spain; Tel: 00-34-600536114; Fax: 00-34-986-276416; E-mails:aristoteles_cerdeira@yahoo.es; carmen.rodriguez.cerdeira@yahoo.es


Abstract

Prophylactic HPV vaccination of both quadrivalent and bivalent vaccines has already been approved in Spain and is gaining popularity among Spanish women. Other European countries show similar trends.

With the use of vaccines against HPV, especially the tetravalent vaccine, in the short or medium-term there will be a lower rate of abnormal cytological results in vaccinated women, which is based on the expected preventive potential, which may range between 50 to 70% of the cases. Furthermore, with the use of the vaccine, in combination with present screening programs, we expect to reach a 92% reduction in the annual number of cases of cervical cancer and other associated pathologies in our country.

Keywords: HPV, bivalent vaccine, tetravalent vaccine.